Article

Discovery and reporting of clinically-relevant germline variants in advanced cancer patients assessed using whole-exome sequencing

2017-03-01

Abstract excerpt

<h4>Purpose</h4> In precision cancer care, WES-based analysis of tumor-normal samples helps reveal somatic alterations but can also identify cancer-associated germline variants important for disease surveillance, treatment choice and cancer prevention. WES can also identify germline secondary findings impacting risk of cardiac, neurodegenerative or metabolic diseases. In patients with advanced cancer, the frequen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 976fe30d-fbb5-50e1-a4be-2c78c7f27d42
DOI: 10.1101/112672

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Discovery and reporting of clinically-relevant germline variants in advanced cancer patients assessed using whole-exome sequencingDOI 10.1101/112672Read

Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study.Semantic proximity Read

Secondary findings in genes related to cancer phenotypes in Turkish exome sequencing data from 2020 individuals.Semantic proximity Read

Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories.Semantic proximity Read

The emerging significance of secondary germline testing in cancer genomics.Semantic proximity Read

Potential advantage of clinical exome sequencing in <i>BRCA1/2</i> -negative families: a retrospective study of a cohort of 500 patients at a high-risk for hereditary cancersSemantic proximity Read

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.Semantic proximity Read

Germline sequencing for presumed germline pathogenic variants via tumor-only comprehensive genomic profilingSemantic proximity Read

ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG)Semantic proximity Read

Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and GenomicsSemantic proximity Read

ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG)Semantic proximity Read

Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.Semantic proximity Read

Exome Sequencing Reveals a High Prevalence of <i>BRCA1</i> and <i>BRCA2</i> Founder Variants in a Diverse Population-Based BiobankSemantic proximity Read